A new assay is available for simple, rapid detection of pathogenic Clostridium difficile in fecal samples using the CE-marked GenRead molecular diagnostics system.

C. difficile infection is rising at an accelerating rate, has become more severe and difficult to treat, and is now more common than healthcare-associated infections (HAIs) caused by methicillin-resistant Staphylococcus aureus (MRSA).

Orion Diagnostica Oy (Espoo, Finland) has launched Orion GenRead C. difficile kit, enabling fast and accurate detection directly from fecal samples. The test supports earlier treatment decisions by detecting strong positive samples in 15 minutes.

Orion GenRead tests are used on the GenRead instrument and are based on SIBA, Orion Diagnostica’s proprietary isothermal nucleic acid amplification technology. SIBA is a robust and highly specific technology that allows fast, continuous amplification of nucleic acids. The use of SIBA in assays combined with the Orion GenRead instrument and its intuitive user interface, enables C. difficile testing outside of traditional PCR laboratories. Together with the portable and easy-to-use GenRead instrument and the fast assay – testing is possible in a wide range of laboratories.

The CE-marked system, consisting of the instrument and the assay, is currently available through Orion Diagnostica’s dedicated distributor network in Europe.

Related Links:
Orion Diagnostica Oy
Orion GenRead system